SCHEMBL2009367

SCHEMBL2009367

CCOC(=O)COc1cc(O)c(C(=O)CN)cc1Cl

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.46
PKM P14618 1/20 0.46
L3MBTL1 Q9Y468 4/20 0.45
TDP1 Q9NUW8 2/20 0.45
TSHR P16473 1/20 0.45
LMNA P02545 1/20 0.43
HMGCR P04035 2/20 0.43
PPOX P50336 1/20 0.43
CASP3 P42574 1/20 0.43
CASP7 P55210 1/20 0.43
CASP9 P55211 1/20 0.43
HPGD P15428 2/20 0.42
ALDH1A1 P00352 4/20 0.41
ESR1 P03372 1/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
NPSR1 Q6W5P4 2/20 0.41
MAPT P10636 1/20 0.41
ABCB1 P08183 1/20 0.40
ADRB3 P13945 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2010341 0.89 HMGCR (0.53) GAAL3MBTL1LMNAHMGCRCASP3
SCHEMBL2012377 0.87 GAA (0.46) GAAPKML3MBTL1TDP1TSHR
SCHEMBL2012142 0.86 MAPT (0.44) PKMLMNAHMGCRCASP3CASP7
SCHEMBL2007639 0.85 GAA (0.49) GAAPKML3MBTL1TDP1TSHR
SCHEMBL2008475 0.82 CASP3 (0.44) L3MBTL1LMNAHMGCRCASP3CASP7
SCHEMBL2009036 0.82 ESR1 (0.42) L3MBTL1LMNAHMGCRCASP3CASP7
SCHEMBL2011477 0.79 GAA (0.40) GAAPKML3MBTL1TDP1TSHR
SCHEMBL2009899 0.78 ALDH1A1 (0.51) GAAPKML3MBTL1TDP1TSHR
SCHEMBL2011344 0.78 ALDH1A1 (0.51) GAAPKML3MBTL1TDP1TSHR
SCHEMBL6558629 0.77 LMNA (0.70) GAAPKML3MBTL1TDP1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7964628-B2 Fibrinogen receptor antagonists and their use PIRAMAL LIFE SCIENCES LIMITED (IN) 2011-06-21 US disclosed
US-20100256161-A1 FIBRINOGEN RECEPTOR ANTAGONISTS AND THEIR USE PIRAMAL LIFE SCIENCES LIMITED (IN) 2010-10-07 US disclosed
US-7759387-B2 Fibrinogen receptor antagonists and their use PIRAMAL LIFE SCIENCES LIMITED (IN) 2010-07-20 US disclosed
US-20070021489-A1 Fibrinogen receptor antagonists and their use NICHOLAS PIRAMAL INDIA LIMITED (IN) 2007-01-25 US disclosed
EP-1677783-A2 FIBRINOGEN RECEPTOR ANTAGONISTS AND THEIR USE Nicholas Piramal India Limited (IN) 2006-07-12 EP disclosed
WO-2005035495-A2 FIBRINOGEN RECEPTOR ANTAGONISTS AND THEIR USE NICHOLAS PIRAMAL INDIA LIMITED (IN) 2005-04-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256161-A1 FIBRINOGEN RECEPTOR ANTAGONISTS AND THEIR USE FGB, F13B, F2 GAA 3340/4885PKM 3583/4885L3MBTL1 4640/4885
US-20070021489-A1 Fibrinogen receptor antagonists and their use FGB, F13B, F2 GAA 3340/4885PKM 3583/4885L3MBTL1 4640/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.